Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1-2 signalling pathway

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 5, 2009, Pages 909-925

  Cai, Jun ^a,b   Yi, Fang Fang ^b   Bian, Zhou Yan ^c,d   Shen, Di Fei ^c,d   Yang, Long ^b   Yan, Ling ^c,d   Tang, Qi Zhu ^c,d   Yang, Xin Chun ^b   Li, Hongliang ^b,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^d WUHAN UNIVERSITY   (China)

Author keywords

Cardiac remodelling; Crocetin; ERK1 2; Fibrosis; NF B; Reactive oxygen species

Indexed keywords

ANTIOXIDANT; CAROTENOID; COLLAGEN; CROCETIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR GATA 4;

ANIMAL; ARTICLE; C57BL MOUSE; CARDIOMEGALY; CELL CULTURE; CELL SIZE; DRUG EFFECT; FIBROBLAST; HEART MUSCLE CELL; MALE; METABOLISM; MOUSE; NEWBORN; OXIDATIVE STRESS; PATHOLOGY; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; ANIMALS, NEWBORN; ANTIOXIDANTS; CARDIOMEGALY; CAROTENOIDS; CELL SIZE; CELLS, CULTURED; COLLAGEN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; GATA4 TRANSCRIPTION FACTOR; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; NF-KAPPA B; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES;

ANIMALIA;

EID: 67249116436     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00620.x     Document Type: Article

References (49)

1. Liehn EA, Merx MW, Postea O, Becher S, Djalali-Talab Y, Shagdarsuren E, Kelm M, Zernecke A, Weber C. Ccr1 deficiency reduces inflammatory remodeling and preserves left ventricular function after myocardial infarction. J Cell Mol Med. 2008 12 : 496 506. (Pubitemid 351555130)
2. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, Chen YE, Yang Q. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med. 2004 10 : 1245 50.
3. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res. 2006 98 : 596 605. (Pubitemid 43755278)
4. Neri M, Cerretani D, Fiaschi AI, Laghi PF, Lazzerini PE, Maffione AB, Micheli L, Bruni G, Nencini C, Giorgi G, D'Errico S, Fiore C, Pomara C, Riezzo I, Turillazzi E, Fineschi V. Correlation between cardiac oxidative stress and myocardial pathology due to acute and chronic norepinephrine administration in rats. J Cell Mol Med. 2007 11 : 156 70.
5. Das DK, Maulik N, Engelman RM. Redox regulation of angiotensin II signaling in the heart. J Cell Mol Med. 2004 8 : 144 52.
6. Das M, Das S, Das DK. Caveolin and MAP kinase interaction in angiotensin II preconditioning of the myocardium. J Cell Mol Med. 2007 11 : 788 97.
7. Das S, Otani H, Maulik N, Das DK. Redox regulation of angiotensin II preconditioning of the myocardium requires MAP kinase signaling. J Mol Cell Cardiol. 2006 41 : 248 55.
8. Petrich BG, Wang Y. Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies. Trends Cardiovasc Med. 2004 14 : 50 5.
9. Yamaguchi O, Watanabe T, Nishida K, Kashiwase K, Higuchi Y, Takeda T, Hikoso S, Hirotani S, Sadamitsu C, Ichijo H, Baccarini M, Hori M, Otsu K. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest. 2004 114 : 937 43.
10. Das S, Das DK. Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Patents Cardiovasc Drug Discov. 2007 2 : 133 8.
11. Li HL, Huang Y, Zhang CN, Liu G, Wei YS, Wang AB, Liu YQ, Hui RT, Wei C, Williams GM, Liu DP, Liang CC. Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and -independent signal pathways. Free Radic Biol Med. 2006 40 : 1756 75.
12. Li HL, Wang AB, Huang Y, Liu DP, Wei C, Williams GM, Zhang CN, Liu G, Liu YQ, Hao DL, Hui RT, Lin M, Liang CC. Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Free Radic Biol Med. 2005 38 : 243 57.
13. Tappia PS, Dent MR, Dhalla NS. Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic Biol Med. 2006 41 : 349 61.
14. Saini HK, Xu YJ, Arneja AS, Tappia PS, Dhalla NS. Pharmacological basis of different targets for the treatment of atherosclerosis. J Cell Mol Med. 2005 9 : 818 39.
15. Makazan Z, Saini HK, Dhalla NS. Role of oxidative stress in alterations of mitochondrial function in ischemic-reperfused hearts. Am J Physiol Heart Circ Physiol. 2007 292 : H1986 94.
16. Meng L, Cui L. Inhibitory effects of crocetin on high glucose-induced apoptosis in cultured human umbilical vein endothelial cells and its mechanism. Arch Pharm Res. 2008 31 : 357 63.
17. Xi L, Qian Z, Xu G, Zhou C, Sun S. Crocetin attenuates palmitate-induced insulin insensitivity and disordered tumor necrosis factor-alpha and adiponectin expression in rat adipocytes. Br J Pharmacol. 2007 151 : 610 7.
18. Kanakis CD, Tarantilis PA, Tajmir-Riahi HA, Polissiou MG. Crocetin, dimethylcrocetin, and safranal bind human serum albumin: stability and antioxidative properties. J Agric Food Chem. 2007 55 : 970 7.
19. He SY, Qian ZY, Wen N, Tang FT, Xu GL, Zhou CH. Influence of crocetin on experimental atherosclerosis in hyperlipidamic-diet quails. Eur J Pharmacol. 2007 554 : 191 5.
20. Xi L, Qian Z, Xu G, Zheng S, Sun S, Wen N, Sheng L, Shi Y, Zhang Y. Beneficial impact of crocetin, a carotenoid from saffron, on insulin sensitivity in fructose-fed rats. J Nutr Biochem. 2007 18 : 64 72. (Pubitemid 44827721)
21. Shen XC, Qian ZY. Effect of crocetin on cardiac hypertrophy induced by overloading pressure in rats. Yao Xue Xue Bao. 2004 39 : 172 5.
22. Shen XC, Qian ZY. Effects of crocetin on antioxidant enzymatic activities in cardiac hypertrophy induced by norepi-nephrine in rats. Pharmazie. 2006 61 : 348 52.
23. Li HL, Liu C, de Couto G, Ouzounian M, Sun M, Wang AB, Huang Y, He CW, Shi Y, Chen X, Nghiem MP, Liu Y, Chen M, Dawood F, Fukuoka M, Maekawa Y, Zhang L, Leask A, Ghosh AK, Kirshenbaum LA, Liu PP. Curcumin prevents and reverses murine cardiac hypertrophy. J Clin Invest. 2008 118 : 879 93.
24. Li HL, She ZG, Li TB, Wang AB, Yang Q, Wei YS, Wang YG, Liu DP. Overexpression of myofibrillogenesis regulator-1 aggravates cardiac hypertrophy induced by angiotensin II in mice. Hypertension. 2007 49 : 1399 408.
25. Liehn EA, Schober A, Weber C. Blockade of keratinocyte-derived chemokine inhibits endothelial recovery and enhances plaque formation after arterial injury in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2004 24 : 1891 6.
26. Liehn EA, Zernecke A, Postea O, Weber C. Chemokines: inflammatory mediators of atherosclerosis. Arch Physiol Biochem. 2006 112 : 229 38.
27. Magesh V, Singh J P, Selvendiran K, Ekambaram G, Sakthisekaran D. Antitumour activity of crocetin in accordance to tumor incidence, antioxidant status, drug metabolizing enzymes and histopathological studies. Mol Cell Biochem. 2006 287 : 127 35.
28. Zhou CH, Qian ZY, Zheng SG, Xiang M. ERK1-2 pathway is involved in the inhibitory effect of crocetin on angiotensin II-induced vascular smooth muscle cell proliferation. Eur J Pharmacol. 2006 535 : 61 8.
29. Zheng S, Qian Z, Sheng L, Wen N. Crocetin attenuates atherosclerosis in hyperlipidemic rabbits through inhibition of LDL oxidation. J Cardiovasc Pharmacol. 2006 47 : 70 6.
30. Ogilvie I, Kennaway NG, Shoubridge EA. A molecular chaperone for mitochondrial complex I assembly is mutated in a progressive encephalopathy. J Clin Invest. 2005 115 : 2784 92.
31. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest. 2005 115 : 500 8.
32. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, Namba M. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation. 1998 98 : 794 9.
33. Shih NL, Cheng TH, Loh SH, Cheng PY, Wang DL, Chen YS, Liu SH, Liew CC, Chen JJ. Reactive oxygen species modulate angiotensin II-induced beta-myosin heavy chain gene expression via Ras-Raf-extracellular signal-regulated kinase pathway in neonatal rat cardiomyocytes. Biochem Biophys Res Commun. 2001 283 : 143 8.
34. Date MO, Morita T, Yamashita N, Nishida K, Yamaguchi O, Higuchi Y, Hirotani S, Matsumura Y, Hori M, Tada M, Otsu K. The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model. J Am Coll Cardiol. 2002 39 : 907 12.
35. 2+ in the inhibition by crocetin of angiotensin II-induced ERK1-2 activation in vascular smooth muscle cells. Eur J Pharmacol. 2007 554 : 85 91. (Pubitemid 44879407)
36. Liang Q, Wiese RJ, Bueno OF, Dai YS, Markham BE, Molkentin JD. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol Cell Biol. 2001 21 : 7460 9.
37. Bisping E, Ikeda S, Kong SW, Tarnavski O, Bodyak N, McMullen JR, Rajagopal S, Son JK, Ma Q, Springer Z, Kang PM, Izumo S, Pu WT. GATA4 is required for maintenance of postnatal cardiac function and protection from pressure overload-induced heart failure. Proc Natl Acad Sci USA. 2006 103 : 14471 6.
38. Perrino C, Rockman HA. GATA4 and the two sides of gene expression reprogram-ming. Circ Res. 2006 98 : 715 6.
39. Oka T, Maillet M, Watt AJ, Schwartz RJ, Aronow BJ, Duncan SA, Molkentin JD. Cardiac-specific deletion of GATA4 reveals its requirement for hypertrophy compensation, and myocyte viability. Circ Res. 2006 98 : 837 45.
40. Pikkarainen S, Tokola H, Kerkelä R, Ruskoaho H. GATA transcription factors in the developing and adult heart. Cardiovasc Res. 2004 63 : 196 207. (Pubitemid 38900834)
41. Navab M, Gharavi N, Watson AD. Inflammation and metabolic disorders. Curr Opin Clin Nutr Metab Care. 2008 11 : 459 64.
42. Sadoshima J, Montagne O, Wang Q, Yang G, Warden J, Liu J, Takagi G, Karoor V, Hong C, Johnson GL, Vatner DE, Vatner SF. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J Clin Invest. 2002 110 : 271 9.
43. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008 132 : 344 62.
44. Baeuerle PA. IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell. 1998 95 : 729 31.
45. Ruiz-Ortega M, Rodrìguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc Res. 2007 74 : 196 206.
46. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007 117 : 568 75.
47. Li P, Wang D, Lucas J, Oparil S, Xing D, Cao X, Novak L, Renfrow MB, Chen YF. Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res. 2008 102 : 185 92.
48. Polyakova V, Miyagawa S, Szalay Z, Risteli J, Kostin S. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med. 2008 12 : 189 208.
49. Liu X, Sun SQ, Hassid A, Ostrom RS. cAMP inhibits transforming growth factor-beta-stimulated collagen synthesis via inhibition of extracellular signal-regulated kinase 1-2 and Smad signaling in cardiac fibroblasts. Mol Pharmacol. 2006 70 : 1992 2003. (Pubitemid 44771915)